Investments in Other Entities (Tables)

9 Months Ended

Sep. 30, 2022

Equity Method Investments and Joint Ventures [Abstract]

Investments in other entities – equity method consisted of the following (in thousands):


	December 31, 2021		Allocation of Income (Loss)		Funding reclassified to loan receivable		Funding		Entity Consolidated		Distribution		September 30, 2022
LaSalle Medical Associates – IPA Line of Business	$	3,034	$	3,885	$	(2,125)	$	—	$	—	$	—	$	4,794
Pacific Medical Imaging & Oncology Center, Inc.	1,719		(20)		—		—		—		—		1,699
531 W. College, LLC – related party	17,230		(420)		—		350		—		—		17,160
One MSO, LLC – related party	2,910		306		—		—		—		(400)		2,816
Tag-6 Medical Investment Group, LLC – related party	4,830		153		—		1,435		(6,418)		—		—
CAIPA MSO, LLC	11,992		493		—		—		—		—		12,485
	$	41,715	$	4,397	$	(2,125)	$	1,785	$	(6,418)	$	(400)	$	38,954

LMA’s summarized balance sheets at September 30, 2022 and December 31, 2021, and summarized statements of operations for the nine months ended September 30, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):

Balance Sheets


	September 30, 2022		December 31, 2021
	(unaudited)		(unaudited)

Assets

Cash and cash equivalents	$	17,996	$	6,619
Restricted cash	699		696
Receivables, net	7,355		2,269
Loan receivable	2,250		2,250

Total assets	$	28,300	$	11,834

Liabilities and Stockholders’ Deficit
Current liabilities	$	33,468	$	32,405
Stockholders’ deficit	(5,168)		(20,571)

Total liabilities and stockholders’ deficit	$	28,300	$	11,834

Statements of Operations


	Nine Months Ended September 30,
	2022		2021
	(unaudited)		(unaudited)

Revenues	$	190,731	$	144,417
Expenses	180,696		155,786

Income (loss) from operations	10,035		(11,369)

Other loss	(48)		—


Net income (loss)	$	9,987	$	(11,369)